Vaccinex Reports 2025 Annual Financial Results
Vaccinex, Inc., a clinical-stage biotechnology company focused on developing novel antibody therapies for Alzheimer’s, Huntington’s disease, and cancer, released its financial results for 2025. The company is advancing its pipeline with plans to initiate a Phase 2b study in Alzheimer's disease, demonstrating ongoing commitment to addressing serious…